Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
Brief Summary: During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.


Options:
A: Arm Label: ADA+MTX/PBO+MTX (Arm 1); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Arm Label: ADA+MTX/ADA+MTX (Arm2); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: ADA+MTX/OL ADA+MTX (Arm 3); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: PBO+MTX/PBO+MTX (Arm 4); Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Biological: placebo | Arm Label: PBO+MTX/OL ADA+MTX (Arm 5); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5) | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4) | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4)
B: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
C: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
D: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo

Answer: D